Anthem Biosciences IPO GMP, Grey Market Premium Today

Anthem Biosciences Limited is preparing to make its debut on the stock market, a long-established pharmaceutical and biotechnology company based in Bengaluru, Karnataka, with solid financial fundamentals and significant growth potential. Anthem Biosciences Limited produces and sells products in the pharmaceutical research and development space as well as contract research and manufacturing services (CRAMS), active pharmaceutical ingredients (APIs), and innovative drug discovery solutions to the global market. The price band of the IPO is ₹540-₹570 per equity share, and based on the GMP there will be a listing premium of about 13.16%. Anthem Biosciences IPO GMP has gotten retail and institutional investors excited, and market observers will be anticipating upcoming results from other pharmaceutical sector IPOs.

IPO Dates for Anthem Biosciences Limited

The Anthem Biosciences Limited IPO is scheduled to open on July 14, 2025, and close on July 16, 2025. The Board of Allotment (BoA) date is expected to be announced by July 17, 2025, with listing planned for July 21, 2025.

IPO Details Summary

Investors are closely monitoring the GMP of Anthem Biosciences ipo, which currently shows strong demand ahead of listing. This IPO is also part of the growing Anthem Biosciences ipo list on the BSE and NSE platforms.

About Anthem Biosciences Limited

Anthem Biosciences Limited is a leading pharmaceutical and biotechnology company located in Bengaluru, Karnataka, India. It operates in the pharmaceutical research and development space and aims to provide end-to-end means to execute contract research and manufacturing services (CRAMS) along with upgrading active pharmaceutical ingredients (APIs), drug discovery, and development services. As a pharmaceutical solutions company in the biotechnology center of Bengaluru, it can take advantage of easy access to scientific brainpower, research infrastructure, and avoid a lot of capital that would have to be installed in the traditional drug development platform to conduct research and development work, and was able to capitalize on and take a significant position in the rapidly expanding pharmaceutical outsourcing ecosystem in India.

Anthem Biosciences Limited has transitioned from being a pharmaceutical research oriented company to a full-service pharmaceutical solutions company offering contract research, manufacturing services, the development of APIs and drug discovery services along with complete business solutions. The company has developed operational capabilities concerned with pharmaceutical research with due diligence in manufacturing excellence, quality assurance, regulatory compliance, and customer service in the competitive pharmaceutical industry with its changes in quantity of demand, technology changes and variations in global regulatory requirements. The company can call on its knowledge of experience across all segments of pharmaceutical research and development and will do everything possible to meet the growing demand, but also to perform pharmaceutical research services, and in so doing take part in pharmaceutical services outsourcing.

Anthem Biosciences anticipates raising ₹3,395 crores from its IPO via an offer for sale by the company's existing shareholders. Funding raised from the IPO will give liquidity to existing investors and promoters and allow the company to pursue its growth strategy. Considering the degree of investor interest from the Anthem Biosciences IPO GMP, alongside the overall market sentiment, there is a cautiously positive outlook in making an investment in the organized pharmaceutical research and development space.

Financial Performance of Anthem Biosciences Limited

The company has shown strong financial performance with consistent revenue growth and profitability across key metrics:

Performance Analysis

Anthem Biosciences Limited has demonstrated robust financial performance with total assets growing from ₹1,618.87 crores in Mar-22 to ₹2,807.58 crores in Mar-25, signifying a considerable leap in asset base and operational capacity. Concurrently, the company's revenues have also shown great growth from ₹1,133.99 crores in Mar-23 to ₹1,930.28 crores in Mar-25, illustrating not only market acceptance of Anthem's pharmaceutical solutions, but also evidence that business scale and market footprint encompass expansion.

Furthermore, Anthem Biosciences has demonstrated consistent profitability with profit after tax across the recent years that has ranged between ₹367.31 crores and ₹451.25 crores, indicating highly efficient operations and sound business fundamentals. In addition, the company's net worth had made observable strides from ₹1,355.00 crores in Mar-22 to ₹2,409.86 crores in Mar-25, reflecting strong financial health and value generation for shareholders.

While their borrowings remain above zero, Anthem's total borrowings in Mar-25 remain very low at ₹108.95 crores. Overall, Anthem's low and manageable level of borrowings indicates many strong cash generation capabilities and strong debt management capabilities. Overall, the strong financial performance based on the Anthem Biosciences ipo gmp today illustrates not only good operational performance but also serves as evidence of investor confidence in Anthem's growth trajectory and its sustainable profitability model.

IPO Share Reservation

The IPO share allocation follows standard SEBI guidelines for main board listings:

Strengths

• Significant revenue increase from ₹1,133.99 crores to ₹1,930.28 crores indicates good growth, potential for further growth, and strong market acceptance

• Consistently profitable, profit after tax of ₹451.25 crores as at Mar-25, reflects operational efficiency

• Solid asset base with total assets of ₹2,807.58 crores providing big operational capacity

• Strong net worth improvement from ₹1,355.00 crores to ₹2,409.86 crores showing strong financial health

• Strategic location in Bengaluru with access to cognitive pharmaceutical talent pool and research ecosystem

• Diverse range of services across pharmaceutical research, manufacturing, and drug discovery services

Risks

• Dependent on pharmaceutical regulatory requirements and compliance across global markets

• Strong competition from established global pharmaceutical players and contract research organizations

• Client concentration risk – potential reliance on key pharmaceutical clients

• Technology obsolescence risk - requires ongoing R&D investment

• Exposed to currency fluctuations due to international business operations and export revenues

How to Apply for Anthem Biosciences Limited IPO?

Step-by-step guide (when IPO opens):

1. Log in to your broker app (Zerodha, Angel One, Groww, etc.)
2. Navigate to the IPO section and select Anthem Biosciences Limited IPO
3. Click "Apply"
4. Enter:
   • Lot size (26 shares minimum)
   • Bid price (₹540–₹570 or select Cut-Off)
   • Your UPI ID
5. Submit the application
6. Approve the UPI mandate in your UPI app (PhonePe, GPay, etc.)

⏰ Important: The mandate must be approved before 5 PM on the same day or before the IPO closes.

How to Check Anthem Biosciences Limited IPO Allotment Status?

You can check the Anthem Biosciences Limited IPO allotment status through BSE/NSE and the registrar portal once the IPO opens.

Check on BSE/NSE

• Visit the BSE or NSE official website
• Navigate to the IPO Allotment Section
• Select Anthem Biosciences Limited IPO
• Enter PAN number or application number
• Submit details to get the BSE/NSE Anthem Biosciences Limited IPO allotment status

Check on the Registrar Portal

• Visit Kfin Technologies Limited's website
• Select IPO allotment status
• Choose Anthem Biosciences Limited IPO
• Enter PAN or application number
• Submit to check status

Company Address

Name: Anthem Biosciences Limited
Address: No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099
Phone: +91 080 6672 400
Email: investors.abl@anthembio.com
Website: https://www.anthembio.com/

IPO Registrar

Name: Kfin Technologies Limited
Address: KFintech, Tower-B, Plot No 31 & 32, Financial District, Nanakramguda, Gachibowli, Hyderabad, Telangana, India - 500032
Phone: +91 40 6716 2222
Email: anthem.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/

Conclusion

Anthem Biosciences presents a compelling investment argument based on India’s exponentially growing pharmaceutical and biotech ecosystem. With excellent revenue and profit margins (i.e. ₹1,930.28 crores (revenue) and ₹451.25 crores (profit)), Anthem Biosciences has good fundamentals. The IPO price range of ₹540–₹570 with an issue size of ₹3,395 crores demonstrates favourable momentum considering the grey market premium (GMP) is ~13.16%.

The company's Headquarters is strategically located in Bengaluru, which has the added advantage of a skilled talent pool and research and development (R&D) infrastructure. In addition, Anthem is well-diversified in its breadth of offerings in contract research, manufacturing, and API development. The outlook for global opportunities in contract research outsourcing continues to be favourable.

Overall, Anthem Biosciences’ strong underlying performance and market positioning makes for a very interesting investment proposal; however, like any investment in the pharmaceutical/biotech sector, investors should consider industry risks from negative regulatory shifts and technological disruption. For the moderate risk investor, Anthem Biosciences appears to offer a strong investment opportunity.

Disclaimer : This analysis is prepared for educational purposes only and should not be considered as financial advice. Investors should consult their financial advisors and conduct thorough research before making investment decisions. Investments in equity markets are subject to market risks, including volatility and sector-specific challenges.

FAQs